CN110337448B - 使用与程序性死亡配体1(pd-l1)结合的抗体的免疫疗法 - Google Patents

使用与程序性死亡配体1(pd-l1)结合的抗体的免疫疗法 Download PDF

Info

Publication number
CN110337448B
CN110337448B CN201780087354.6A CN201780087354A CN110337448B CN 110337448 B CN110337448 B CN 110337448B CN 201780087354 A CN201780087354 A CN 201780087354A CN 110337448 B CN110337448 B CN 110337448B
Authority
CN
China
Prior art keywords
seq
antibody
light chain
heavy chain
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780087354.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN110337448A (zh
Inventor
弗兰克·J·卡尔佐内
严海
约翰·张
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Remd Biotherapeutics Inc
Original Assignee
Remd Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Remd Biotherapeutics Inc filed Critical Remd Biotherapeutics Inc
Publication of CN110337448A publication Critical patent/CN110337448A/zh
Application granted granted Critical
Publication of CN110337448B publication Critical patent/CN110337448B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780087354.6A 2016-12-23 2017-12-23 使用与程序性死亡配体1(pd-l1)结合的抗体的免疫疗法 Active CN110337448B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662438622P 2016-12-23 2016-12-23
US62/438,622 2016-12-23
PCT/US2017/068369 WO2018119475A1 (en) 2016-12-23 2017-12-23 Immunotherapy using antibodies that bind programmed death ligand-1 (pd-l1)

Publications (2)

Publication Number Publication Date
CN110337448A CN110337448A (zh) 2019-10-15
CN110337448B true CN110337448B (zh) 2023-08-08

Family

ID=62627185

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780087354.6A Active CN110337448B (zh) 2016-12-23 2017-12-23 使用与程序性死亡配体1(pd-l1)结合的抗体的免疫疗法

Country Status (6)

Country Link
US (1) US11332531B2 (https=)
EP (1) EP3559045A4 (https=)
JP (1) JP7128529B2 (https=)
CN (1) CN110337448B (https=)
RU (1) RU2766582C2 (https=)
WO (1) WO2018119475A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
CN109843327B (zh) 2016-07-07 2022-05-13 小利兰·斯坦福大学托管委员会 抗体佐剂缀合物
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
CN110914302A (zh) 2017-06-01 2020-03-24 赛托姆克斯治疗学股份有限公司 可活化抗pdl1抗体及其使用方法
CA3095076A1 (en) * 2018-03-29 2019-10-03 Adagene Inc. Anti-pd-l1 antibodies and use thereof
WO2020190725A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
JP2023511362A (ja) * 2020-01-21 2023-03-17 ボルト バイオセラピューティクス、インコーポレーテッド 坑ｐｄ－ｌ１抗体
IL295434A (en) 2020-02-21 2022-10-01 Macrogenics Inc cd137 binding molecules and their uses
WO2021216832A1 (en) * 2020-04-23 2021-10-28 Remd Biotherapeutics, Inc. Chemokine receptor 4 (cxcr4) antagonist antibodies
IL308918A (en) * 2021-06-09 2024-01-01 Shanghai Epimab Biotherapeutics Co Ltd Antibodies and bispecific binding proteins that bind OX40 and/or PD-L1
EP4412636A4 (en) * 2022-06-01 2025-09-17 Remd Biotherapeutics Inc NOVEL INTERFERON VARIANTS AND BIFUNCTIONAL FUSION MOLECULES THEREOF
EP4638504A1 (en) * 2022-12-19 2025-10-29 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-pdl1 antibodies and uses thereof
CN120813375A (zh) 2023-01-30 2025-10-17 凯玛布有限公司 抗体
CN117126282B (zh) * 2023-10-26 2024-01-12 迈威(上海)生物科技股份有限公司 抗体及其在制备阻断αvβ8与Latent TGF-β的结合的药物中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2412494C (en) * 2000-06-22 2012-10-23 Genentech, Inc. Agonist anti-trk-c monoclonal antibodies
US7514078B2 (en) * 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
EP1544291A4 (en) * 2002-07-19 2006-08-02 Towa Kagaku Co Ltd A NEW METHOD FOR THE PRODUCTION OF ANTIBODY CYME, NEW ANTIBODY CYM AND USE THEREOF
PT1907424E (pt) * 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
KR100882445B1 (ko) 2007-03-16 2009-02-09 울산대학교 산학협력단 항―４－１ｂｂ 항체를 이용한 항원 특이적 자가유래ｃｄ８＋ｔ 세포의 분리 및 증식 방법
CN101868246A (zh) * 2007-09-21 2010-10-20 加利福尼亚大学董事会 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性
US20110311550A1 (en) * 2008-10-24 2011-12-22 The Scripps Research Institute Agents for hcv treatment
EP3255060A1 (en) * 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
RU2011131071A (ru) * 2008-12-26 2013-02-10 Дзе Юниверсити Оф Токио Диагностика и лечение рака с помощью антитела против lgr7
WO2010109924A1 (ja) * 2009-03-25 2010-09-30 国立大学法人東北大学 Ｌｈ型二重特異性抗体
JP2012034668A (ja) * 2010-08-12 2012-02-23 Tohoku Univ ヒト型化抗ｅｇｆｒ抗体リジン置換可変領域断片及びその利用
US9540443B2 (en) * 2011-01-26 2017-01-10 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies
JP6072771B2 (ja) * 2011-04-20 2017-02-01 メディミューン，エルエルシー Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
KR101764096B1 (ko) * 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
DK3237446T3 (en) * 2014-12-22 2021-07-26 Pd 1 Acquisition Group Llc Anti-PD-1-antistoffer
RU2017129236A (ru) * 2015-01-26 2019-03-07 Макродженикс, Инк. Мультивалентные молекулы, содержащие dr5-связывающие домены

Also Published As

Publication number Publication date
WO2018119475A1 (en) 2018-06-28
RU2766582C2 (ru) 2022-03-15
RU2019121086A3 (https=) 2021-09-03
EP3559045A4 (en) 2020-08-19
EP3559045A1 (en) 2019-10-30
US11332531B2 (en) 2022-05-17
US20200190197A1 (en) 2020-06-18
JP7128529B2 (ja) 2022-08-31
JP2020514277A (ja) 2020-05-21
CN110337448A (zh) 2019-10-15
RU2019121086A (ru) 2021-01-25

Similar Documents

Publication Publication Date Title
CN110337448B (zh) 使用与程序性死亡配体1(pd-l1)结合的抗体的免疫疗法
JP7165995B2 (ja) 細胞傷害性ｔリンパ球抗原－４（ｃｔｌａ－４）に結合する抗体を使用した癌治療
EP4281484B1 (en) Anti-her-2/trop-2 constructs and uses thereof
CN110366564B (zh) 使用与程序性死亡1(pd-1)结合的抗体的免疫疗法
US11242398B2 (en) Anti-OX40 antibodies and methods of activating OX40
US20260109770A1 (en) C-c chemokine receptor type 8 (ccr8) antagonist antibodies
WO2021216832A1 (en) Chemokine receptor 4 (cxcr4) antagonist antibodies
CN115803062B (zh) 滋养层细胞表面抗原2(trop-2)抗体
US12617857B2 (en) Chemokine receptor 4 (CXCR4) antagonist antibodies
CN112203685A (zh) 使用结合白细胞介素-17a(il-17a)的抗体的自身免疫紊乱和炎性紊乱的治疗

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant